HCG Manavata launches awareness campaign for prostate cancer
Encouraging early detection and breaking the silence around men’s health
Encouraging early detection and breaking the silence around men’s health
The projected business potential is around US$ 1 million in the first year
cSCC is one of the most common cancers in the U.S. and globally
The company showcased three core programs developed through this platform
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Subscribe To Our Newsletter & Stay Updated